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Different cell types have unique combinations of ion channels and receptors that 
define their physiological function. Combinations of ion channel and receptor isoforms 
may change in a cell-specific manner with disease progression. Thus, it is essential to 
design a general platform to investigate the descriptive properties of cell types and 
understand their role in health and disease. In this dissertation, I contributed to constellation 
pharmacology, a platform to assess phenotypic properties of individual cell types based 
on the combinations (constellations) of ion channels and receptors expressed in the plasma 
membrane. 
To validate the platform, major cell types were identified in the pacemaking circuit 
of mice ventral respiratory column (VRC), a region that generates and maintains 
respiratory rhythm. The cell-specific constellations of three major cell types were 
characterized and the properties of putative inspiratory neurons were examined in intact 
brainstem slice preparations by electrophysiological recordings. This work revealed new 
neuromodulators of the respiratory pacemaking circuit that were validated using intact slice 
preparations.  
To test the application of constellation pharmacology in identifying molecular 
changes in disease states, the molecular correlates of neuropathic pain were investigated. 
Concerted multivalent molecular changes were observed in the sensory neurons of rat 
dorsal root ganglia following chronic constriction injury and sciatic nerve ligation injury 
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that resulted in the appearance of aberrant neuronal phenotypes, which upregulated with 
the progression of pain states. This work demonstrated the strength of constellation 
pharmacology in monitoring neuronal phenotypes with the progression of disease states.   
Constellation pharmacology requires the use of target selective pharmacological 
tools to uncover the combinations of ion channels and receptors in cell membrane. The ion 
channels and receptors exist in complex heteromeric isoforms for which selective 
pharmacological tools are not well explored. The applicability of this platform to screen 
for novel bioactive marine natural products with potential for targeting these ion channel 
isoforms was demonstrated by identifying novel neuroactive peptides from a new 
superfamily of snails, Crassispiridae.  
Thus, in this dissertation, I establish the application of constellation pharmacology 
to 1) describe different cellular phenotypes based on the membrane constellations, 
2) investigate changes to cellular phenotypes in pathological conditions and 3) discover 
bioactive marine natural products. 
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Understanding brain functions, in both normal and diseased states, requires 
elucidation of the cellular properties and the cellular interconnections that form a 
functional circuit. At the present time, the different cell types that form the circuitries in 
virtually all regions of the brain are incompletely understood and this creates a divide 
between molecular and systems neuroscience. In this dissertation, I helped develop an 
experimental approach to bridge this gap by identifying and characterizing different cell 
types that are present at any given locus of the nervous system based on the specific 
isoforms of ion channels and receptors expressed in the plasma membrane of each cell 
type. Describing cell types by their cell-specific combinations of receptors and ion 
channels has the potential to create a bridge between molecular and systems neuroscience 
and will provide insights into changes that occur during the development of disease 
states. 
 
Cell types and constellation pharmacology 
Conventionally, neuronal cell types have been defined based on morphology (eg: 
rod, cones, pyramidal, ganglion), neurotransmitter released (eg: cholinergic, 
dopaminergic, GABAergic), the person who discovered them (eg: Purkinje cell, Merkel 
cell, Retzius cell) or by combining electrical properties with anatomical location (eg: fast 
spiking neurons of striatum). From an evolutionary perspective, a cell type can be defined 
as “a set of cells in an organism that change in evolution together, partially independent 
of other cells, and are evolutionary more closely related to each other than to other cells” 
(1). These examples demonstrate the complexity of defining cell types and call for a 
comprehensive strategy to resolve this issue.  Recent strategies focus on neuron-type- 
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specific gene batteries (called terminal selectors) that are uniquely expressed/regulated in 
differentiated neuronal types (1, 2). This strategy unifies many properties of cells such as 
enzymes for neurotransmitter synthesis, ion channels that regulate membrane potential, 
synaptic proteins, adhesion molecules and morphological properties like arborizations to 
define the core identity of a neuron, yet how these terminal selector genes are regulated 
remains unknown. Through a complementary approach, some cell types can be 
genetically labeled based on a cell-type-specific gene uniquely expressed in each cell 
type (3-5), but it is becoming increasingly evident that these target genes may be more 
broadly expressed than originally expected (6). In this dissertation, I use an experimental 
paradigm called constellation pharmacology to interrogate neuronal cell types. 
Constellation pharmacology is a term used to describe the approach of uncovering 
constellations (combinations) of ion channels and receptors found in different cell types 
that are revealed by the application of target selective pharmacology. This approach is 
based on the principle that different cell types uniquely express cell-specific 
constellations of ion channels and receptors that define their functional phenotypes.  
 
Ion channels and receptor diversity 
Constellation pharmacology aims at uncovering the combinations of ion channels 
and receptors that are unique to each cell type. The majority of ion channels and receptors 
exist in complex heteromeric isoforms that are difficult to identify due to lack of target 
selective pharmacological tools. Classic examples that demonstrate receptor complexity 
are voltage-gated potassium channels (7), nicotinic acetylcholine receptors and NMDA 
receptors (8-10). These ion channels and receptors are composed of different subunits 
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that can be assembled in various combinations, which increases receptor complexity and 
diversity. The contribution of these heteromeric ion channels in shaping the membrane 
properties of cells is largely unknown and requires target selective pharmacological tools 
for thorough investigation.  
 
Conopeptides: pharmacological tools to study ion channels  
and receptor diversity 
Cone snails are marine gastropods that evolved large cocktails of venom peptides 
and small molecules to capture prey and deter predators and competitors. The molecular 
targets of most conopeptides are receptors and ion channels in the nervous system of their 
prey and are excellent tools to study complex isoforms of ion channels and receptors. 
Several comprehensive reviews have been published that detail the molecular diversity 
and therapeutic potential of >10,000 species of venomous marine snails (10, 11). Inspired 
by the definition: cabals are secret societies plotting to overthrow the government, these 
groups of toxins were named toxin “cabals” based on the physiological end points 
achieved by a group of peptides when injected in prey (“lightning-strike cabal”, “motor 
cabal” and “nirvana cabal” cause excitatory shock, flaccid paralysis and drowsiness 
respectively)(12). A well-studied species of cone snail, Conus geographus, elegantly 
explains this concept. Motor cabal of Conus geographus venom has these major 
components: w-conotoxin GVIA, a-conotoxin GI and µ-conotoxin- GIIIA, GIIIB, GIIIC 
that are used together to paralyze fish by targeting neuromuscular circuitry of fish in the 
following three ways: 1) w-conotoxin GVIA blocks presynaptic voltage-gated calcium 
channels (Cav2.2) and inhibits neurotransmitter release from the presynaptic terminus, 
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(2) a-conotoxin GI blocks the postsynaptic nicotinic acetylcholine receptors and prevents 
their activation by the neurotransmitters released by the presynaptic terminus and (3) µ-
conotoxin- GIIIA, GIIIB, GIIIC directly inhibit action potentials at the muscle membrane 
by blocking voltage-gated sodium channels expressed in muscle membrane (13). These 
peptide cabals were also the inspiration for constellation pharamacology as “cabals” 
target “constellations” of ion channels and receptors to achieve a physiological end point. 
In addition to cone snails (Conidae), there are other venomous snails such as Turridae, 
Terebridae, Colubraridae, etc. that also have rich diversity of venom peptides, but the 
toxinology of these snails are yet to be explored.  
 
Broad goals of this dissertation 
By using the experimental paradigm called “constellation pharmacology”, my 
goals are to 1) define major cell groups that network in a well-defined locus, 2) identify 
changes to cellular phenotypes in disease states and 3) discover new pharmacological 
tools for better characterization of ion channels and receptors. 
 
To use constellation pharmacology to identify cell-specific  
constellations of ion channels and receptors found 
 in functional circuits   
Model system: ventral respiratory column (VRC) of neonatal mice 
VRC in the brainstem of mice contains the pacemaker circuit that generates and 
maintains respiratory rhythm. It is hypothesized that within the VRC, there are 
specialized pacemaking circuits that control three phases of breathing: inspiration, post-
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inspiration and active expiration, that are regulated by the pre-Bötzinger complex (pre-
BötC), post inspiratory complex (PiCo) and the lateral parafacial nucleus, respectively 
(14).  Of these, the pre-BötC is well studied and the application of substance-P to a slice 
containing the pre-BötC is known to elicit rhythmic network activity consistent with 
normal breathing pattern (15). Furthermore, when pre-BötC neurons in a slice are isolated 
from the network by blocking fast synaptic transmission, SP elicits bursting within 
inspiratory neurons. Thus, only a subset of preBötC neurons (putative inspiratory 
neurons) express the NK1 receptor (16). The circuitry contains many other cell types that 
are selectively active during expiration, gasping and this model system is chosen to 
identify cell-specific constellations in major cell types that are found in this circuitry that 
can be validated by electrophysiological recordings from these physiologically relevant 
cell types. 
 
To monitor changes to cellular phenotypes with the  
progression of disease states 
Model system: dorsal root ganglia (DRG) of adult rodents 
 The constellation of ion channels and receptors may change in a cell-specific 
manner in disease states and the goal of this project is to monitor concerted molecular 
changes that may occur in different cell types with the progression of disease. DRG is an 
excellent model system as it contains sensory neurons that relay information such as 
touch, itch, pain, etc. to higher centers in the nervous system. These neurons are 
pseudounipolar and send peripheral projections to innervate visceral organs, skin, muscle 
and bones (for sensory perception) and central projections to neurons within the spinal 
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cord that transmit sensory signals to the brain for central processing. It is hypothesized 
that DRG contains ~25 neuronal cell types that may be distinguished by their different 
physiological roles (mechanosensor, thermosensor, proprioceptor, pruriceptor, 
nociceptor, etc.), firing thresholds, myelination and electrical properties. In addition, 
various kinds of injury to DRG have been well-established as model systems to study 
neuropathic pain (17, 18). These injuries cause hypersensitivity to innocuous sensory 
stimuli and result in allodynia and hyperalgesia following nerve injury. The molecular 
mechanisms underlying neuropathic pain is unknown because neither the specific cell 
types, nor the critical molecular changes, are comprehensively identified. In this 
dissertation, I aim to identify changes to cellular and molecular phenotypes following 
neuropathic nerve injury to DRG by using two injury models: chronic constriction injury 
(CCI) and spinal nerve ligation (SNL). 
 
To use constellation pharmacology to screen for  
novel bioactive compounds. 
As described in section 1.3, venom peptides are excellent tools to study complex 
isoforms of ion channels and receptors. After decades of research, various conopeptides 
have been characterized (10). The goal of this project is to use constellation 
pharmacology as a platform to identify new toxins that are functionally related to 
previously characterized conopeptides. This approach will help expand the library of 
venom peptide tools to study the increasing diversity of ion channels and receptors. To 
test the application of constellation pharmacology in identifying new bioactive 
compounds, the peptides from a unique branch of venomous turrids, the family 
	 8 
Crassispiridae, were investigated. In particular, peptides from Crassispira cerithina, were 
tested on dissociated neurons from mice DRG and their activity was compared with 
previously characterized conopeptides to assess molecular targets.   The biology of 
crasssipirine snails is not well known and only one peptide Cce9a has been reported 
previously (19). In this work, I tested the activity of two peptides, Cce9a and Cce9b, and 
compared it with previously characterized conotoxin kJ-PlXIVA (20).  
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 Remarkable advances have been made in understanding the neural circuitry that 
underlies pain. In addition to defining the nociceptive circuitry and identifying which 
neurons comprise these circuits, the cell-specific molecular changes that take place when 
a pathological chronic pain state is established need to be systematically elucidated. 
Knowing which cells change, and identifying the specific functional changes that take 
place in each of the relevant cell types, is a prerequisite for establishing an integrated 
cellular and molecular framework for chronic pain.  
In this work, we demonstrate the application of constellation pharmacology (1) as 
a platform to monitor phenotypic changes that take place in a population of DRG neurons 
as a chronic pain state is established. DRG contains many different types of sensory 
neurons and it is of interest to observe how different cell types respond to nerve injury. 
The constellation pharmacology approach examines hundreds of neurons simultaneously 
by their individual responses to the application of different pharmacological challenges 
using calcium imaging. Some of the questions addressed in this work are the following: 
When chronic pain is established, what changes take place in the combinations of ion 
channels and receptors expressed in DRG neurons? How do these changes affect cellular 
phenotypes? Are some of these molecular changes that take place in these neurons 
coordinated? What molecular changes accompany the progression to neuropathic pain 
states? 
 For the present study, we have used two models of neuropathic pain: Chronic 
Constriction Injury (CCI) and Spinal Nerve Ligation (SNL) of the rat (2, 3). These are 
well-validated animal models for the chronic pain state that often follows nerve injury.  
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The results with the CCI and SNL rats suggest that the onset of chronic pain is 
accompanied by an increase in the frequency of neurons responding to bradykinin, with 
exaggerated effects observed in the SNL model compared to CCI. It is well known that 
bradykinin potently elicits pain, and there are widespread observations in the literature 
suggesting that bradykinin is linked in its activity to a number of ion channels and 
receptors expressed in sensory neurons (4). We have focused our analysis on DRG 
neurons that responded to the application of bradykinin. Constellation pharmacology has 
allowed us to observe subsets of DRG neurons that are affected by the increase in 
bradykinin receptor expression, and whether other changes in ion channel and receptor 
functions are also observed in these neurons. In addition, we performed phenotypic 
assessment of these bradykinin responsive neurons with the progression of neuropathic 
pain following day 1, 3, 6 and 14 post SNL injury.  
We report a set of significant molecular changes in ATP, acetylcholine, 
bradykinin and capsaicin responsive neurons that result in the appearance of new 
subclasses of bradykinin responsive DRG neurons as a consequence of CCI and SNL 
injury. Some of the changes appear to occur in a concerted manner, which suggests 
simultaneous downstream effects of the nerve injury on the constellations of ion channels 
and receptors in subsets of DRG neurons. These concerted changes raise the possibility of 
developing a complementary combination of therapeutic drugs to prevent, reverse or 
inhibit the aberrant neuronal activity resulting from such concerted changes that 




Material and methods 
Animals 
Adult, male Sprague-Dawley rats (200-250 g at the time of surgery, Envigo, 
Indianapolis, IN) were used. All procedures were performed in accordance with the 
guidelines of the Committee for Research and Ethical Issues of IASP under protocols 
approved by the University of Arizona Institutional Animal Care and Use Committee. 




Chronic constriction injury (CCI) 
CCI surgeries were done according to the description of Bennet et al. (11). 
Briefly, rats were anesthetized with 5% isofluorane in air at 1 L/min and maintained with 
2.5% isofluorane. The sciatic nerve was exposed at mid-thigh level. Four loose ligatures 
using 4-0 chromic gut suture were placed around the exposed sciatic nerve about 2 mm 
apart. Sham-operated animals underwent the same procedure but without the ligatures to 
the sciatic nerve. The cold allodynia and mechanical hyperalgesia of the rats was assessed 
before and at D14 after the surgery prior to euthanasia and tissue collection. 
 
L5/L6 spinal nerve ligation (SNL)  
The surgical procedure for L5/L6 SNL was performed according to Kim and 
Chung (12). Briefly, anesthesia was induced with 5% and maintained with 2.5% 
isofluorane in air. A 2 cm midline incision was made and the lumbar 5 and 6 spinal 
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nerves (L5/L6) were exposed and tightly ligated with 4-0 silk suture. The incision was 
closed and the animals were returned to their home cages. Sham-operated control rats 
were prepared in an identical manner except that the L5/L6 spinal nerves were not 
ligated. The tactile and thermal hypersensitivity of the rats was assessed before and at 
specific days after the surgery prior to euthanasia and tissue collection.  
 
Behavioral tests 
Assessment of cold allodynia and mechanical hyperalgesia  
Cold allodynia was evaluated by placing rats on a metal plate maintained at 4 ºC. 
The frequency and accumulated duration of guarding the injured hind paw was measured 
for 2 min. The assessment of mechanical hyperalgesia consisted of measuring the 
withdrawal threshold of the paw both ipsilateral and contralateral to the site of nerve 
injury in response to continuously-increased pressure using a Randall Selitto apparatus 
(Ugo-Basile algesymeter, Stoelting, Chicago, IL) (13). A sharp withdrawal of the paw or 
vocalization is the end point. The paw withdrawal thresholds for each hindpaw were 
assessed 3 times. Cutoff was set at 500 g to avoid tissue injury. Hyperalgesia were 
expressed as the difference between the average ipsilateral and contralateral paw 
withdrawal thresholds. 
 
Evaluation of tactile and thermal thresholds  
The withdrawal threshold of the hindpaw was measured in response to probing of 
the plantar surface with a series of calibrated von Frey filaments (Stoelting, Wood Dale, 
IL) in logarithmically spaced increments ranging from 0.41 to 15 g (4–150 N). Each 
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filament was applied perpendicularly to the plantar surface of the left hindpaw of rats 
held in suspended wire-mesh cages. Withdrawal threshold was determined by 
sequentially increasing and decreasing the stimulus strength (“up and down” method), 
analyzed using a Dixon nonparametric test and expressed as the mean withdrawal 
threshold (14-17).  The withdrawal latency of the hindpaw to an infrared radiant heat 
source was performed as previously described (18-20). Rats were allowed to acclimate 
within a Plexiglas enclosure on a clear glass plate for 30 min. An infrared heat source 
was directed on the glass plate underneath the plantar surface of the left hindpaw. A 
motion detector halted both lamp and timer when the paw was withdrawn. Baseline 
latencies were established around 20 s to allow a sufficient window for the detection of 
possible hyperalgesia. A maximal cutoff of 33 s was used to prevent tissue damage. 
%hypersensitivity was calculated as (baseline - post injury)/baseline x 100%. 
 
Statistical analysis 
All results were expressed as mean ± SEM. Statistical analyses were calculated 
using GraphPad Prism 7 software. An unpaired t-test (two-tailed) was used when only 
two groups were compared; the t and P values are reported in the Results section. For 
three or more group comparisons, a One-Way ANOVA post-hoc Tukey’s multiple 
comparisons test was used for between-group comparisons. The F(DFn,DFd) and P 
values are reported for the ANOVA tests; post hoc comparison is reported as 





DRG cell culture 
Two weeks after the surgeries, the lumbar DRG of all animals were dissected. For 
CCI trials, DRG from L4, L5 and L6 were pooled from both the ipsilateral and 
contralateral side of both experimental and sham-operated control animals. For SNL 
trials, L5and L6 DRGs were pooled from both the ipsilateral and contralateral side of 
both experimental and sham-operated control animals, while L4 DRG was cultured 
separately. The pain state of the animals was assessed by monitoring cold allodynia. The 
tissues were stored separately in cell culture medium and shipped on ice overnight. DRG 
fragments were kept on ice, transferred to a tissue culture-treated (by vacuum gas plasma) 
Petri dish (BD Biosciences) with HBSS (ThermoFisher, cat# 14175103) and cleaned to 
remove debris and excessive tissue. The DRGs were chopped using spring scissors and 
transferred with a large-diameter fire-polished Pasteur pipette to a 15-mL conical tube. 
The total volume was adjusted to 900 µL with HBSS; 100 µL 2.5% (wt/vol) trypsin were 
added (for a working concentration of 0.25% (wt/vol) trypsin), and the tube was 
incubated at 37 °C in a water bath for 18 min. The contents of the tube were mixed three 
or four times during the trypsin incubation by gently flicking the tube. After incubation, 
the DRG neurons were washed three times with 4 mL cell culture medium. Each wash 
was performed by adding 4 mL cell culture medium, allowing DRGs to settle to the 
bottom of the tube and removing as much medium as possible with a fire-polished 
Pasteur pipette without removing any DRGs. After the final wash, DRGs were 
resuspended in 1.5 mL cell culture medium. The DRG suspension was triturated 5–10 
times (or until there was no resistance) through a series of fire-polished pipettes, where 
each successive pipette had a smaller tip diameter. The solution became cloudy as 
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individual neurons dissociated from the ganglia. Any undissociated tissue was carefully 
removed using a Pasteur pipette. The suspension was centrifuged at 50 X g for 10 min. 
After centrifugation of the cell suspension, the supernatant was removed by aspiration, 
leaving behind the volume of medium required to plate dissociated DRG neurons, 
typically into two wells (40µL total). Neurons were resuspended in the remaining 
medium by gentle trituration with a 200-µL disposable plastic pipette tip. In general, 3 
DRG ganglia tissue (L4, L5, L6 from one side of an animal) yielded a 40uL volume of 
cell suspension that was plated in two wells.  
 
Plating cells 
Silicone rings were cut with cork borers from 0.25-mm-thick silicone sheets 
(Grace BioLabs). Each ring had an outer diameter of ~10 mm and an inner diameter of ~3 
mm. The rings were washed sequentially with 70% (vol/vol) ethanol and deionized, 
filtered water, 100% ethanol and 70% ethanol and dried. Each silicone ring was placed on 
the floor of a well of a poly-D-lysine–coated 24-well tissue culture plate (BD 
Biosciences) and sealed to the floor with gentle pressure applied with the tips of a pair of 
dull forceps.   
20 µL cell suspension was added to the center of each silicone ring of the multi-
well plate and the plates were placed in the 37 °C incubator for 45–60 min to allow cells 
to settle and adhere. After 60 min, 1mL cell culture medium was added and the plates 
were placed in a 37 °C, 5% CO2 tissue culture incubator, and the cultures were used for 




Loading cells with Fura-2-AM and calcium imaging 
 After culturing overnight, the 24-well plate was placed in a sterile tissue culture 
hood; 1 mL culture medium in each well was agitated by pipetting it up and down 
vigorously in the well to suspend all dead cells and dislodge any cells that were only 
loosely adherent.  
The medium was replaced with 500 µL fresh cell culture medium containing 2.5 
µM Fura-2-AM, which was freshly prepared by thawing the single-use stock aliquot of 1 
mM Fura-2-AM (ThermoFIsher, cat# F-1221) in DMSO and adding it to cell culture 
medium followed by vigorous vortexing for ~20 s. The plate was placed in the 37 °C 
incubator for 1 h, after which the medium was replaced with 1 mL fresh MEM + 
supplements, and the plate of cells was allowed to equilibrate to room temperature for 20 
min. Just before imaging a particular well, the MEM + supplements solution in the well 
was replaced with observation solution. The observation solution was replaced two 
additional times to completely remove free Fura-2-AM. 
 
Digital video microscopy 
All images were obtained with a 10x objective on an inverted microscope (Nikon 
Eclipse Ti-U). A Sutter Instruments Lambda DG light source (300-W Xenon arc lamp) 
fitted with a filter wheel was used as the source of excitation light at 380 and 340 nm. 
Images were acquired with an Andor Zyla sCMOS camera and Nikon NIS elements 
software.  
After loading with Fura-2-AM, a 24-well plate was fastened to the microscope 
stage. A bright-field image of a single field of view was captured and used to select 
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regions of interest (ROIs) corresponding to the area (delineated by the outer perimeter) of 
all nonoverlapping cells in the field. Each ROI, corresponding to a single cell, was 
monitored for [Ca2+]i. Typically, >100 neurons were imaged for each experiment. The 
fluorescence emission was monitored at 510 nm for both 380- and 340-nm excitation. 
The exposure time was adjusted for each experiment to a maximum ROI intensity of 
~3,500 gray levels for 380-nm excitation and ~1,000 gray levels for 340-nm excitation. 
An image was captured at each excitation wavelength, and the ratio of fluorescence 
intensities at excitation wavelengths of 340 and 380 nm was acquired one time every 1 or 
2 s to monitor the relative changes in calcium concentration in each cell as a function of 
time. Nikon NIS elements software generated a calcium response profile in the form of a 
trace with 340/380 nm ratios on the y-axis and time on the x-axis. 
 
Preparation of solutions  
Cell culture medium 
The medium for culturing dorsal-root ganglion (DRG) neurons was minimal 
essential media MEM (Invitrogen) supplemented with 10% (vol/vol) FBS (Hy-Clone) 
penicillin (100 U/mL), streptomycin (100 µg/mL), 1X Glutamax (Invitrogen), 10 mM 
Hepes and 0.4% (wt/vol) glucose. The medium was adjusted to a pH of 7.4 with NaOH, 
filtered through a 0.22-µm filter under sterile conditions and stored at 4 °C until shortly 
before use, when it was allowed to warm to 37 °C in a tissue culture incubator with 5% 





DRG observation solution 
 The observation solution for calcium-imaging and immunostaining experiments 
consisted of 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM sodium 
citrate, 10 mM Hepes and 10 mM glucose. A 10X stock of observation solution (but 
without sodium citrate or glucose) was prepared with penicillin streptomycin at 100 
U/mL and 100 µg/mL, respectively, and stored at 4 °C. No additional penicillin 
streptomycin was added to the 1X observation solution. Sodium citrate and glucose were 
added to the 1X solution to yield their final concentrations given above. The final 
solution was adjusted to a pH of 7.4 with NaOH, and stored at 4 °C until used.  
For membrane depolarization by high extracellular potassium, [K+]o , 30 mM 
[K+]o in DRG observation solution was made from a stock of 100 mM high K+ solution. 
A stock of 100 mM high K+ solution was made by adding 50 mM NaCl, 100 mM KCl, 2 
mM CaCl2, 1 mM MgCl2, 1 mM sodium citrate, 10 mM Hepes, 10 mM glucose and 
1mL 10X penicillin-streptomycin, adjusted to a pH of 7.4 with NaOH and stored at 4 °C 
until used.  The osmolarity of this stock solution is equivalent to that of DRG observation 
solution because an equimolar concentration of NaCl is replaced by KCl. 
 
Ligand concentrations 
 All stock solutions of ligands for calcium-imaging were stored at −20 °C in 
small-volume aliquots to avoid repetitive freezing and thawing, with the exception of 
allyl isothiocyanate, which was stored at 4 °C. All working concentrations were obtained 
by diluting stock solutions into DRG observation solution. Stocks were 1 M acetylcholine 
(Sigma cat# A6625) in water, 10 mM adenosine triphosphate (Sigma cat# FLAAS-1VL) 
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in water, 2 mM bradykinin (Tocris, cat# 3004) in water, 640 mM (1R, 2S, 5R)-(-)-
menthol (Sigma, cat# M2780) in ethanol, allyl isothiocyanate (mustard oil) (Sigma-




 Calcium signals were elicited by a ~15-s application of various ligands in DRG 
observation solution. The observation solution was aspirated from the well with a 
peristaltic pump controlled by a foot pedal, and observation solution containing a 
working concentration of ligand was applied manually at the edge of the well from a 1mL 
pipette tip. After 15 s, the ligand solution was replaced completely with observation 
solution in the same manner. After an additional 40 s and 1 min after the application of 
ligand, the observation solution was replaced with a second and third aliquot of 
observation solution, respectively. This procedure was repeated as necessary, generally at 
5-min intervals for various ligands. The order of ligand application was chosen such that 
the more hydrophobic and less reversible ligands were applied towards the end (such as 
AITC and capsaicin) and reversible ligands were applied towards the beginning of an 
experiment.  
After the video microscopy protocols, cells were stained with Alex-568–labeled 
isolectin B4 (IB4) (ThermoFisher cat# I21412) at a concentration of 2.5 µg/mL in DRG 
observation solution for >5 min followed by three washes with DRG observation solution 





 After the experiments were performed on all wells, the 24-well plate was 
removed from the microscope stage. DRG observation solution was aspirated and washed 
with ice-cold DRG observation solution 2 times.  The cells were fixed with 4% ice-cold 
paraformaldehyde in PBS for 30 min at room temperature on a shaker. After 30 min, 
paraformaldehyde was aspirated and cells were washed 3 times with ice-cold DRG 
observation solution. Cells were permeabilized with 0.25% Triton X-100 in DRG 
observation solution for 30 min at room temperature on a shaker. After the 
permeabilization step, cells were washed 3 times with ice-cold DRG observation solution 
and were treated with a blocking buffer for 30 min at room temperature on a shaker. The 
blocking buffer consisted of 10% normal donkey serum (Jackson Immunoresearch cat # 
017-000-121) in DRG observation solution and 30 mM glycine. The cells were washed 2 
times with ice-cold DRG observation solution.  1 mL of anti-CGRP primary antibody 
(1:2000 dilution, Immunostar cat# 24112) in 0.1% donkey serum was added to the wells 
and the cells were incubated with primary antibody overnight at 4 oC on a shaker. The 
primary antibody was aspirated and cells were washed 3 times with ice-cold DRG 
observation solution. 1 mL secondary antibody (1:200 dilution, Thermofisher cat#A-
21206) in DRG observation solution was added and cells were incubated with secondary 
antibody for 1 h at room temperature on a shaker. The cells were washed with DRG 
observation solution 3 times. Bright field and fluorescent images were taken on the 
microscope. To identify the same field of view, previously created ROIs were overlayed 





The time course of the 340:380 ratio for each ROI (trace) was analyzed using a 
set of R functions (R Core Team 2013) for quantitative analysis of peak heights, 
clustering and determination of cell-phenotype percentages as described previously (5). 
Neuronal cell populations were compared using a logistic regression of binary response 
score onto population type nested within experiment date. To compare ipsilateral CCI 
neurons to contralateral CCI neurons, the glm function of R was used as: glm(bin ~ 
ipsi/date, family="binomial") where bin is a response indicator (0,1), ipsi is 1 for neurons 
from the ipsilateral CCI and 0 for neurons from the contralateral CCI, and date is the date 
of the experiment.   
The responses to the application of ligands were also scored manually in a binary 
format (0 or 1 for absence and increase of calcium influx, respectively). The baseline 
calcium level for each cell trace was observed and a response was assigned as positive 
calcium influx (value=1), if the magnitude of calcium influx was higher than a threshold 
of 0.05 units (of 340/380 ratio) above the baseline. In rare cases where the calcium 
response to the application of previous ligand did not return to baseline, a mild deflection 
of calcium signal was assessed to call for a positive a response.  In general, a 5 min or 7 
min interval between applications was used to obtain a fully reversible calcium profile.  
 
Results 
Behavioral studies following CCI and SNL nerve injury 
 Figure 3.1 shows the behavioral assays performed on rats following CCI and SNL 
nerve injury. As shown in Figure 3.1A, the rats display higher sensitivity to cold with 
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increased frequency of paw withdrawal (Figure 3.1A) and increased duration of 
withdrawal events (Figure 3.1B) following CCI injury. In SNL injured rats, thermal and 
mechanical hypersensitivity were observed following injury. The threshold to thermal 
stimulus reduced in injured rats compared to the baseline scores monitored before the 
injury, and to sham-operated rats (Figure 3.1C). Similarly, the withdrawal threshold to 
mechanical sensitivity also decreased significantly compared to scores before injury and 
to sham operated animals (Figure 3.1D), (p<0.05 for all behavioral studies).   
 
Changes in membrane receptor compositions of DRG  
neurons following CCI and SNL injury 
A primary culture of dissociated DRG cells was prepared and analyzed using 
constellation pharmacology. Seven pharmacological challenges were given (indicated by 
the arrows) and examples of responses from individual neurons are shown in each trace. 
A peak signifies an increase in cytosolic calcium concentration, [Ca]i, in response to the 
pharmacological challenge. Each specific pharmacological challenge may or may not 
elicit a transient increase in calcium as monitored by fluorescence of the calcium-
sensitive dye Fura 2 using two wavelengths. In the experiments shown, examples of the 
diverse responses of individual neurons in the same well are illustrated for both the 
control contralateral DRG cultures and the ipsilateral DRG cultures from the CCI and 
SNL animals.  
The responses to the application of 30 mM [K+]o was used to differentiate neurons 
from non-neuronal cells. In addition to responses elicited by [K+]o, the diversity of 
response patterns to six pharmacological challenges is quantitated in Table 3.1. For CCI 
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trials, DRG neurons from 13 CCI operated rats and 11 sham-operated rats were analyzed 
and for SNL trials, neurons from 5 SNL operated and 4 sham operated rats were 
analyzed. Although there is some variation in the three uninjured DRG groups 
(contralateral CCI and ipsilateral and contralateral DRG from sham-operated animals), 
the data reveal a significant divergence in the frequency of cells responding to the 
pharmacological challenges in the ipsilateral CCI DRG neurons (Table 3.1). Figure 3.2 
summarizes these molecular changes following CCI and SNL injury. As shown in Figure 
3.2A, there was a decrease in the frequency of neurons responding to acetylcholine 
(p<0.05) and capsaicin (p<0.001) in the ipsilateral CCI, and a significant increase in the 
frequency of neurons responding to ATP and bradykinin (p<0.001). These observations 
align with previous studies performed on whole DRG (6-8). These differences were 
extensively upregulated in SNL operated rats as shown in Figure 3.2B. We have 
specifically investigated the increase in the frequency of DRG neurons that respond to 
bradykinin in the injured ipsilateral DRG neurons of the CCI- and SNL-operated rats.  
For the ease of understanding these data sets, we have grouped data obtained from 
uninjured DRG neurons ( contralateral CCI, sham-operated ipsilateral and contralateral 
DRG neurons) and labeled them as “CCI controls” and similarly grouped data obtained 
from uninjured DRG neurons from SNL-operated and sham-operated rats (SNL 
ipsilateral L4, SNL contralateral L4, SNL contralateral L5L6, sham-operated ipsilateral 
and contralateral L4, L5 and L6) and labeled them as “SNL control”. As noted in Table 
3.1, there were no differences observed between uninjured DRG neurons in their 




Assessing the behavioral changes with the progression  
of neuropathic pain 
We performed behavioral assays and constellation pharmacology experiments on 
injured DRGs at different time points following SNL injury to identify the behavioral and 
molecular changes with the progression of pain states. As shown in Figure 3.3A, the 
SNL-injured rats display progressive reduction in thresholds to mechanical stimulus 
(Figure 3.3A) and heat stimulus (Figure 3.3B) starting at 3, 6 and 14-day post SNL 
injury.  These scores were compared with sham-operated rats and baseline scores prior to 
nerve injury. As shown in Figure 3.3, rats do not display any allodynia on Day 1, but 
begin to develop tactile allodynia (p<0.05) and thermal hyperalgesia (p<0.001) on Day 3 
following injury.    
 
Tracking molecular changes with the progression to  
neuropathic pain states 
To identify the earliest molecular changes that appear following nerve injury, 
SNL injured rats were behaviorally monitored at Day 1, 3, 6 and 14 after injury as shown 
in Figure 3.4. The acetylcholine responsive neurons significantly reduced in SNL-injured 
DRG at Day 1 (11%± 2% of the total neurons, p<0.001) compared to controls (33% ± 4% 
of total neurons). In addition, there was a significant increase in ATP responsive neurons 
(75% ± 2% of total neurons, p<0.001) in SNL-injured DRG at Day 1 compared to 
controls (44%± 4% of the total neurons). Capsaicin responsive neurons began to reduce 
starting Day 3 and continued to decrease until Day 14. Progressive increase in bradykinin 
responsive neurons were observed at Day 3, 6 and 14 as shown in Figure 3.4. Thus, we 
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monitored the molecular changes that appeared with the progression of pain states and 
the resulting effects in bradykinin responsive neuronal phenotypes. 
 
Grouping DRG neurons based on phenotypic calcium profiles 
 In the experiments summarized in Figure 3.2, the frequency of neurons 
responding to bradykinin in all of the control groups was similar (~12% ± 2%). In 
contrast, the frequency of bradykinin responsive neurons obtained from injured DRG 
were approximately two-fold higher in ipsilateral CCI (34% ± 2%) and five-fold higher 
in ipsilateral SNL L5L6 (66% ± 2%). Although the frequency of cells responding to 
bradykinin varied from experiment to experiment, the ipsilateral DRG neurons from CCI 
and SNL consistently showed a significant increase (p<0.001) compared to contralateral 
DRG neurons in all experiments on animals that displayed chronic pain states in 
behavioral assays.  
An alternative analysis of the data is to classify subsets of cells that have a 
particular pharmacological profile as shown in Figure 3.5. The bradykinin responsive 
neurons were categorized in 5 groups based on their responses to the application of other 
pharmacological agents and their frequency of appearance is summarized in Figure 3.6. 
Group 1 neurons, in addition to responding to bradykinin, also respond to both menthol 
and capsaicin. Furthermore, the response of these neurons to AITC is very robust. In 
contrast, Group 2 neurons do not respond to menthol, but uniformly respond to capsaicin. 
There is heterogeneity in their response to AITC, but the response is not robust, if it 
occurs. These two groups appear to be canonical bradykinin responsive neurons and they 
were observed in all cell cultures as indicated in Figure 3.6. Groups 3-5 neurons were 
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absent in control cultures from CCI and SNL and appeared only in injured DRG 
(ipsilateral CCI and ipsilateral SNL L5L6). Thus, the appearance of three new phenotypic 
groups of bradykinin responsive neurons with distinctive pharmacological profiles 
contributed towards the majority of increase in bradykinin responses show in Figure 3.2. 
Group 3 neurons responded to ATP and bradykinin only and contributed towards 11% 
increase in bradykinin responses from ipsilateral CCI culture and 30% increase in 
ipsilateral SNL L5L6 (shown in Figure 3.6A). Group 4 neurons were defined based on 
their magnitude of response to acetylcholine and ATP. In this group, the magnitude of 
ATP responses was higher than acetylcholine and they generally responded to the 
application of AITC. Similar to group 3, these neurons appeared only in ipsilateral CCI 
and SNL L5L6 and were absent in all controls. The pharmacological profile of Group 5 is 
a hybrid between Groups 3 and 4. Unlike Group 4 neurons, these did not respond to 
acetylcholine, but like Group 4 neurons, responded to ATP and to AITC. They differ 
from the Group 3 neurons that uniformly did not respond to the application of AITC. 
There were additional (~8%) bradykinin responsive neurons that appeared in SNL 
ipsilateral L5L6 cultures in addition to the five groups described above and these have 
not been grouped as they require more detailed analysis. Thus, Group 1 and 2 are more 
canonical neurons that may include polymodal peptidergic nociceptors found in controls, 
ipsilateral CCI and ipsilateral SNL L5L6. The CCI and SNL injury result in the 
appearance of three new groups that are shown in Figure 3.5 (Group#3- 5). 
In addition, the incremental increase in bradykinin responsive neurons that was 
observed at 3, 6 and 14 days post injury (Figure 3.4) were phenotypically assessed and 
the progressive increase in bradykinin responses appeared from the new cellular 
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phenotypes described above (Figure 3.5, Group# 3-5). The quantitative analysis of these 
phenotypes, as shown in Figure 3.6B, demonstrate that the new bradykinin responsive 
neurons are absent at Day 1 following injury and begin to appear and increase starting 
Day 3 post injury.  
 
Coordinated changes in three different receptors based on  
the magnitude of responses to ligand application 
In addition to the frequency of responses, the magnitudes of calcium responses 
were assessed. An example of coordinated changes associated with the increased 
responsiveness to bradykinin emerged through the analysis of the neurons that responded 
to both ATP and acetylcholine (Figure 3.7). Figure 3.7A shows phenotypic calcium-
imaging traces of neurons from ipsilateral CCI DRGs that were responsive to both 
acetylcholine and ATP. Figure 3.7C shows similar traces from ipsilateral SNL DRGs. 
These have been sorted further into two groups: those that also responded to bradykinin 
and those that did not. We observed that in the neurons that express the bradykinin 
receptor, the calcium transient in response to ATP was generally greater than the calcium 
transient in response to acetylcholine. However, in the class of neurons that did not 
respond to bradykinin, the converse was usually true. This relationship is illustrated using 
a log plot as shown in Figure 3.7B and Figure 3.7D. The plot shows the logarithm of the 
ratio of the magnitude of responses of acetylcholine to ATP in each cell. In the controls, 
the responses to acetylcholine are commonly greater than the responses to ATP. In 
addition, the plot demonstrates that there is a leftward shift of the curve associated with 
ipsilateral CCI, suggesting that a significant proportion of neurons that responded to both 
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acetylcholine and ATP now exhibit a larger magnitude of response to ATP than to 
acetylcholine. This effect is more pronounced in ipsilateral SNL cultures, as shown in 
Figure 3.7D. In contralateral CCI, 28% percent of these neurons (grey arrow) had higher 
ATP magnitude than acetylcholine and the majority of neurons (72%) had higher 
magnitude of acetylcholine than ATP. In ipsilateral CCI, an increased percentage of 
neurons (39%) had an ATP response magnitude that was greater than acetylcholine and 
the majority of these neurons were responsive to bradykinin. Thus, in the cluster of 
neurons represented to the left of the vertical line in Figure 3.7B, there are coordinated 
changes compared to the controls: (1) the response to ATP became greater than the 
response to acetylcholine (not observed in most control neurons), and (2) a high 
proportion of neurons with an acetylcholine/ATP response <1 became responsive to 
bradykinin. Thus, the constellation of functional ion channels and receptors was altered in 
three different receptors and ion channels to yield the distinctive pharmacological profile 
found in a subset of ipsilateral DRG neurons.   
In SNL cultures, the same trends were also evident and more pronounced. Only 
29% of the neurons had acetylcholine responses greater than ATP responses, whereas in 
contralateral SNL cultures, 93% of the neurons had a phenotype where ACh magnitude 
was greater than ATP magnitude. Thus, DRG neurons from ipsilateral SNL exhibit 
profound concerted changes in receptor expression: significant upregulation of ATP 
receptors and downregulation of ACh receptors, accompanied by new expression of 





Effects of nerve injury on IB4 and CGRP stains 
 The cells were stained with isolectin B4 (shown in red, IB4 conjugated with 
Alexa 564 dye) to identify non-peptidergic nociceptors and an antibody for CGRP 
(shown in green, secondary antibody conjugated with Alexa 488 dye) to identify 
peptidergic nociceptors. In neurons subjected to CCI, the percentages of IB4 and CGRP 
stained neurons were reduced and nearly absent in ipsilateral SNL cultures, as shown in 
Figure 3.8. The bradykinin responsive cell groups were analyzed for these stains.  Group 
1 and Group 2 neurons were largely positive for CGRP in controls. In contrast, the new 
cell groups that appear in ipsilateral CCI and ipsilateral SNL L5L6 cultures (Groups 3-5, 
Figure 3.5) were negative to both IB4 and CGRP stains. These staining data suggest that 
multivalent molecular changes occur in different cell types (unlabeled cell, IB4+cells and 
GCRP+ cells) that result in convergence to new bradykinin responsive neuronal 
phenotypes. It is also notable that the majority of the IB4- CGRP- neurons in control DRG 
were capsaicin responsive, and a significant fraction of these cells did not respond to 
capsaicin in the ipsilateral CCI and SNL L5L6 DRG. These results are suggestive of 
coordinated, multivalent changes in ATP, bradykinin and capsaicin receptors in a subset 




 We analyzed functional phenotypic changes that occur in DRG neurons when a 
pathological chronic pain state is established after CCI and SNL.  Neurons from the 
ipsilateral lumbar DRG from CCI and SNL were compared to multiple controls, 
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including neurons from the contralateral DRGs of the same animal and from ipsilateral 
and contralateral DRGs from sham-operated animals. There were no significant 
differences observed between the three control DRG cultures. In contrast, significant 
differences were detected between neurons from ipsilateral DRG of CCI/SNL rats and 
controls.  
 One of the most notable observations was the increase in the fraction of DRG 
neurons that responded to bradykinin (Figure 3.2). The increase in the number of DRG 
neurons expressing these receptors can be accounted for by three distinctive neuronal 
subclasses, as described in Figure 3.5. One neuronal subclass responded to bradykinin 
and ATP. The DRG neurons that share this profile accounted for approximately half of 
the observed increase in the overall frequency of neurons responding to bradykinin 
(Figure 3.6A).  
Another subset of neurons expressed bradykinin receptors with a distinctive 
pharmacological profile found only in the injured ipsilateral CCI and SNL DRG, and not 
the uninjured control DRGs that also responded to ATP and acetylcholine as is illustrated 
in Figure 3.7. In controls, the neurons that responded to both acetylcholine and ATP 
mostly exhibited a greater response to ACh than to ATP. A significant fraction of all 
neurons that responded to both compounds in the injured DRG trials exhibited a relative 
increase in the response magnitude to ATP, and a relative decrease in the response 
magnitude to acetylcholine (demonstrated by the left-shifted segment of the red curve in 
Figure 3.7B and Figure 3.7D). The detailed phenotypic response of these cells is shown 
by the last two traces displayed in Figure 3.7A: a profile found in the ipsilateral DRG 
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cultures from CCI- and SNL-operated animals and absent in the controls, suggesting a 
concerted molecular interplay between acetylcholine, ATP and bradykinin receptors.  
In addition, another example of coordinated changes was observed in capsaicin 
responsive neurons. The extreme downregulation of capsaicin responsive neurons 
suggests that TRPV1 expression is decreased following CCI and SNL injury. It is unclear 
how the reduction in TRPV1 could lead to pain states as TRPV1 has been conventionally 
associated with nociception, although TRPV1 receptor itself may not mediate pain signal 
(9). Nevertheless, this observation requires investigation of constellations of other 
receptors within the TRPV1 expressing neurons that could provide hints on how these 
combinatorial changes result in a physiologically relevant neuropathic pain state.  
A third subset of neurons with a pharmacological profile found only in the 
experimental neurons (from ipsilateral DRGs in CCI and SNL rats) is illustrated in Figure 
3.5 as the Group #5. These neuronal phenotypes appear to represent a subset of the Group 
4 neurons that have lost their responsiveness to ACh completely. Together, Groups 3, 4 
and 5 account for the majority of increase in the frequency of DRG neurons that respond 
to bradykinin in the ipsilateral CCI and SNL DRGs, are only found in injured DRG and 
were absent in uninjured DRG.  
In addition to changes in receptor compositions, we also observed decrease in the 
expression of CGRP and binding of IB4. These changes in neurons from injured DRG 
(ipsilateral CCI and SNL) suggests two hypotheses: 1) once pain state is established, 
previously non-nociceptive neurons begin to express markers of nociceptive neurons, 
such as upregulated expression of bradykinin and ATP receptors, and/or 2) the properties 
of nociceptive neurons change by losing IB4 binding and/or CGRP expression in addition 
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to the many changes in receptor and ion channel expression. Together, these changes 
could result in the appearance of new phenotypic neuronal groups as shown in Figure 3.5 
(Group#3-5). 
To monitor the earliest molecular events that occur following nerve injury, we 
performed a series of experiments at Day 1, 3, 6 and 14 following SNL injury. As shown 
in Figure 3.3, the behavioral tests to assess the thresholds for tactile and thermal 
sensitivity reduced starting Day 3. The corresponding molecular changes are shown in 
Figure 3.4. As shown, at Day 1 following nerve injury, the pain scores of animals tested 
were similar to sham-operated rats but some molecular changes already began to appear 
in DRG with a decrease in ACh responsive neurons and an increase in ATP responsive 
neurons. This suggests that changes in ACh- and ATP-responsive neurons are necessary, 
but not sufficient to establish neuropathic pain. The decrease in behavioral thresholds 
correlated with increase in bradykinin responsive neurons and suggests that coordinated 
changes in ACh, ATP, bradykinin, and capsaicin are required to result in neuropathic 
pain. These coordinated changes are phenotypically examined and illustrated in Figure 
3.5 and Figure 3.7.  
Two questions that arise are: does the appearance of these new phenotypes 
contribute towards neuropathic pain or do these phenotypes appear as a result of nerve 
injury? These questions require further investigation like 1) testing pharmacological 
interventions that alleviate chronic pain and observing their effects on the appearance of 
these aberrant neuronal phenotypes 2) using a cocktail of pharmacological blockers of 
ATP and bradykinin receptors and observe its effect on rat behavior following nerve 
injury. Thus, the current work opens new avenues to explore chronic pain studies at 
  
42 
cellular and molecular levels. In this study, we have defined a set of functional changes in 
receptor and ion channel expression that result in appearance of new neuronal phenotypes 
using constellation pharmacology, demonstrating that this approach can be used to 
monitor cellular and molecular changes in pathological states in other animal models of 
disease, even when genetic tools are not readily available.   
In addition, the novelty of these experiments is demonstrated by tracking the 
coordinated changes in membrane constellations within individual neurons, as opposed to 
studying the global transcriptional changes in whole population of DRGs where cell-
specific changes and functional changes are unknown. Among other implications, this 
approach paves the way to a new paradigm of identifying drugs that could focus on 
reducing/preventing the progression of neuronal cell types to the three new bradykinin 
































Figure 3.1: Summary of behavioral assays performed on rats subjected to CCI and 
SNL injury 
A shows the number of times rats lifted their paws (number of guarding events). B shows 
the duration of guarding events in response to cold plate assay performed after CCI 
injury. A and B show that the CCI-operated rats had significantly higher number of 
guarding events and guard duration compared to sham-operated rats. C indicates the 
threshold to lift paw in response to heat stimulus. D indicates the threshold to respond to 
mechanical stimulus to injured paw after SNL injury. As shown, the SNL injured rats 
show thermal and mechanical hypersensitivity following SNL injury. For CCI, behavioral 
experiments were performed 10 days after injury. For SNL, behavioral experiments were 
performed 14 days after injury. SNL injured animals were tested before and after surgery. 
SNL BL: Baseline score obtained from animal before SNL surgery, SNL D14: 14-days 
post SNL surgery, Sham BL: Base line score obtained from sham-operated animal before 
surgery, Sham D14: Sham-operated animals 14-days post-surgery. For CCI, n=13 rats 
and 11 sham-operated rats; For SNL n=5 SNL-operated and 5 sham-operated rats. 









Figure 3.2:  Summary of profiling experiments from CCI and SNL injured DRG 
neurons 14-days after injury 
The plots show the average percentage of neurons that responded to the applications of 
pharmacological ligands. ACh: 1mM acetylcholine, ATP: 20uM ATP, BR: 10uM 
bradykinin, ME: 400uM Menthol, AITC: 100uM allyl isothiocyanate, C: 500nM 
capsaicin. A compares neurons from injured CCI DRG with uninjured DRG neurons and 
the percentage of ATP and bradykinin responsive neurons are significantly higher 
compared to controls (explained in main text), whereas the percentage of acetylcholine- 
and capsaicin-responsive neurons were decreased. The number of neurons and number of 
trials compared are: ipsilateral CCI= 5035 neurons from 33 trials, contralateral CCI=4519 
neurons from 29 trials, ipsilateral sham=2176 neurons from 21 trials, contralateral 
sham=2028 neurons from 17 trials. The data were obtained from 13 CCI-operated and 11 
sham-operated rats. *=p<0.05, **=p<0.01, ***=p<0.001 
B summarizes the average percentage of neurons that responded to the application of 
pharmacological ligands in SNL injured DRG compared to uninjured DRGs. The neurons 
responsive to bradykinin and ATP were significantly increased after SNL injury, and the 
acetylcholine- and capsaicin-responsive neurons were significantly lower compared to 
uninjured DRG neurons. The number of neurons and trials compared were: ipsilateral 
SNL L5L6= 1028 neurons from 5 trials, contralateral SNL L5L6= 960 neurons from 5 
trials, sham ipsilateral L5L6= 714 neurons from 4 trials, sham contralateral L5L6 = 277 
neurons from 2 trials. The data were obtained from 5 SNL-operated rats and 4 sham-







































































Figure 3.3: Monitoring the progression of pain behaviors due to SNL injury  
The panels show the behavioral test scores obtained for SNL injured rats after 1, 3, 6 and 
14-days post-surgery compared with sham-operated rats. A compares tactile sensitivity 
and B compares thresholds for thermal sensitivity of SNL injured rats with sham-
operated rats. As shown, the threshold for tactile and thermal stimulus gradually 

















Figure 3.4: Monitoring molecular changes with the progression of neuropathic pain 
induced by SNL injury. SNL injury induced molecular changes at Day 1, 3, 6 and 14 
after injury. The earliest changes were observed in the frequency of neurons responsive to 
acetylcholine and ATP. Only 11%±2%  of total neurons obtained from injured DRG were 
responsive to ACh compared to 33%±4% in uninjured DRGs (controls) on Day 1 
following SNL injury. The bradykinin responsive neurons progressively increased 












Figure 3.5: New bradykinin responsive neuronal phenotypes appear following CCI 
and SNL injury. The bradykinin responsive neurons were categorized into 5 phenotypic 
groups based on their calcium response phenotypes to the application of pharmacological 
ligands. Each calcium-imaging trace is a representative response profile from a single 
neuron within the group. Group 1 and Group 2 are bradykinin responsive neurons that 
responded to capsaicin. Group 1 neurons responded to menthol, whereas Group 2 neurons 
did not. Group 3-5 are bradykinin responsive neurons that were insensitive to capsaicin. 
Neuronal profiles shown in Group 3-5 were found only in injured DRG neurons 
(ipsilateral CCI and ipsilateral SNL L5L6 cultures) and were absent in uninjured DRG 
(controls). 
X-axis (Time in minutes): sequential application of pharmacological ligands monitored 
over an hour. Arrows indicate 15 s application of the following: KCl: 30mM potassium 
chloride, ACh: 1mM acetylcholine, ATP: 20uM ATP, BR: 10uM bradykinin, ME: 
400uM Menthol, AITC: 100uM allyl isothiocyanate, C: 500nM capsaicin. Y-axis: Ratio 















   



















Figure 3.6: Quantitative analysis of bradykinin responsive neuronal phenotypes 
A: Quantifying the appearance of new bradykinin responsive neurons in CCI and 
SNL DRGs. The phenotypic profiles of bradykinin responsive neuronal groups shown in 
Figure 3.5 were quantified. Groups 1 and 2 were found in all trials (injured experimental 
trials and uninjured control trials) and accounted for 12%±4% of the total neurons. In 
CCI and SNL injured DRG neurons, the net increase in bradykinin responsive neurons 
found 14 day post injury was accounted by the appearance of new phenotypes as shown 
in Figure 3.5 (Group#3-5). 30%±3% of the total neurons found in SNL ipsilateral L5L6 
had phenotypic profiles of Group 3 and these phenotypic profiles appeared in injured CCI 
DRG with frequency of 11%±3% of the total neurons. Groups 4 and 5 also appeared only 
in injured SNL DRGs (4%±1%  and 11%±2%,  respectively) and CCI injured DRG 
(3%±1% and 5%±2%, respectively) and were absent in injured DRG. y-axis: Percentage 
of total neurons with phenotypic profiles shown in Figure 3.5, x-axis: Type of DRG 
tissue 14-days post-surgery. B: Tracking the appearance of new bradykinin-
responsive neuronal phenotypes in SNL DRGs with the progression of neuropathic 
pain: The new bradykinin responsive neuronal groups (shown in Figure 3.5, Group # 3-
5) did not appear on Day 1 and started to appear at Day 3, further upregulated at Day 6 
and 14 after SNL injury. The progressive increase in bradykinin responsive neurons (as 
shown in Figure 3.4) is accounted by the appearance of new bradykinin responsive 











































 Figure 3.7: Coordinated changes observed by comparing magnitude of responses 
The neurons that responded to the application of both acetylcholine and ATP were 
compared. A: ACh and ATP responsive neurons in CCI cultures. A new bradykinin-
responsive cell group appears in CCI cultures and a majority of these neurons had ATP 
response magnitude greater than ACh as shown in the last two traces. C: ACh and ATP 
responsive neurons in ipsilateral SNL L5L6. A majority of these neurons were bradykinin 
responsive and similar to neurons from CCI, the new cell group (Group #4 in Figure 2) 
appeared only in ipsilateral SNL L5L6 cultures and not in the controls. The percentage of 
neurons with ACh magnitude <ATP magnitude is significantly higher in ipsilateral SNL 
cultures. B,D: Co-ordinated changes plotted on logarithmic scale to compare 
magnitudes of acetylcholine and ATP responsive neurons: 
The neurons represented in Figure 3.7A and 3.7C were plotted in logarithmic scale to 
compare the percentage of neurons based on the magnitude of responses to acetylcholine 
and ATP. X-axis is log scale of ACh:ATP. The vertical line represents the point where 
the magnitude of ACh and ATP are equal. The horizontal arrow determines the rank i.e. 
the percentage of neurons that have higher magnitude of ATP than ACh. Figure 3.7B: 
Comparison of ipsilateral CCI cultures with contralateral CCI. There is a leftward shift in 
ipsilateral CCI cultures indicating that more neurons have higher magnitude of ATP. The 
+ symbols indicate that a lot of these neurons are bradykinin responsive (data from Figure 
3.7A included) Figure 3.7D: Comparison of ipsilateral SNL L5L6 cultures with 
contralateral SNL L5L6 cultures. The plot reveals that not only a greater proportion of 
neurons (71% of ACh+ ATP+ neurons) have higher magnitude of ATP than ACh 
(leftward shift) compared to contralateral SNL L5L6 (7% of ACh+ ATP+ neurons) but 
also indicates a loss of neurons that have higher ACh magnitude than ATP in ipsilateral 
SNL L5L6 (29%) compared to contralateral SNL L5L6 (93%). These coordinated 
changes between ACh, ATP and BR suggest that appearance of new bradykinin 
responsive cell groups and loss of canonical ACh responsive groups could be causative of 
neuropathic pain. For Figure 3.7B, 614 neurons (163 BR responsive) from ipsilateral CCI 
were compared with 644 neurons (34 Br responsive) from contralateral CCI. For Figure 
3.7D, 70 neurons (43 BR responsive) neurons from ipsilateral SNL L5L6 were compared 
with 173 neurons (5 BR responsive neurons) from contralateral SNL L5L6. The data 
were obtained from 14 CCI rats and 5 SNL rats, respectively.  
 








































Figure 3.8: Effects of CCI and SNL injury on IB4 and CGRP stains 
A, B, C are images of cell cultures obtained from control, ipsilateral CCI and ipsilateral 
SNL L5L6, respectively. The bright field image was overlaid with fluorescent images 
obtained for IB4 and CGRP staining. IB4 was conjugated to Alexa 546 dye (red) and the 
secondary antibody for anti-CGRP was conjugated with Alexa 488 dye (green). The 
percentage of neurons that were stained with IB4 and CGRP decreased with CCI and 
SNL injury as shown in D. For D, number of neurons compared are: ipsilateral CCI= 
1019 neurons from 4 trials, control CCI=1282 neurons from 8 trials, ipsilateral SNL 
L5L6=797 neurons from 2 trials, control SNL=1910 neurons from 12 trials. Data 





































Table 3.1: Summary of profiling experiments 
The table describes the average percentage of neurons that responded to the application 
of other pharmacological agents in each tissue group. DRG neurons from injured 
ipsilateral CCI and ipsilateral SNL L5L6 are compared with the uninjured DRG from 
contralateral side and sham-operated rats. ACh= 1mM acetylcholine, ATP= 20uM ATP, 
BR= 10uM bradykinin, ME=400uM menthol, AITC= 100uM AITC, C= 500nM 
capsaicin. As shown in table, the percentage of acetylcholine and capsaicin responsive 
neurons significantly decreased in ipsilateral CCI and SNL L5L6 cultures and the 
percentage of ATP and bradykinin responsive neurons increased significantly. For CCI, 
data were obtained from 13 CCI-operated rats, 11 sham-operated rats and for SNL, data 
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 Current drug discovery efforts focus on drug candidates acting on molecular targets 
identified from an established pathological state. The concerted molecular changes that 
occur in specific cell types during disease progression are generally undefined. Thus, 
systematically developing therapeutics for molecular targets whose function is required for 
disease progression is currently not feasible because neither the specific cell types, nor the 
critical molecular changes, have been identified. In this dissertation, I demonstrate the 
application of constellation pharmacology to address these problems.  
In Chapter 2, the cell-specific constellations of major cell types were identified in 
neonatal mice VRC that form functional circuits to generate and maintain respiratory 
rhythm. The functional phenotypic diversity that was observed in dissociated cell culture 
was recapitulated in intact brainstem slice preparations and was validated by 
electrophysiological recordings from putative inspiratory neurons. This work highlighted 
the strength of constellation pharmacology in generating testable hypotheses and in 
obtaining novel modulators for physiologically relevant cell types (demonstrated for 
inspiratory neurons in this study). An extension of this work will focus on obtaining 
transgenic mice and labeling subsets of neurons (inspiratory, expiratory etc.) with 
genetically encoded fluorescent proteins to expand the information on constellation of ion 
channels and receptors expressed in shaping the phenotype of these cell types.               
Chapter 3 demonstrates the use of constellation pharmacology platform to monitor 
changes to cellular phenotypes as a result of molecular changes that appear with the 
progression of pathological states. By using two models of neuropathic pain, CCI and SNL, 
I identified new groups of bradykinin responsive neurons that appeared in injured DRG. In 
addition, coordinated, multivalent molecular changes were observed that resulted in 
		
83 
phenotypic changes in different cell types. Opiates are the most commonly prescribed 
analgesics for neuropathic pain and there is an alarming increase in overdose-induced 
deaths and addiction. By elucidating the functional changes and properties of aberrant 
neuronal subtypes, we hope to devise suitable therapeutic interventions as an alternative to 
opiates.  
The first (and key) step of identifying the appearance of aberrant neuronal 
phenotypes was achieved by using constellation pharmacology. As described before, ion 
channels and receptors exist in complex heteromeric isoforms that are largely neglected 
due to lack of selective pharmacological tools to study them.  In Chapter 4, I demonstrate 
the applicability of constellation pharmacology to screen for novel pharmacological tools 
with potential for targeting ion channel subtypes. The activity of venom peptides (Cce9a 
and Cce9b) from a new family of venomous snails, Crassispira cerithina, was compared 
with previously characterized conotoxin (kJ-pl14a) from Conus planorbis by using 
constellation pharmacology and was found to target voltage-gated potassium channels.  
Thus, in this dissertation, I establish the application of constellation pharmacology 
and 1) described different cellular phenotypes based on the membrane constellations, 
2) investigated changes to cellular phenotypes in pathological conditions, and 3) 
discovered novel bioactive marine natural products that target complex isoforms of ion 
channels and receptors.  
 
